Related references
Note: Only part of the references are listed.Glucocorticoids increase CD4+CD25high cell percentage and Foxp3 expression in patients with multiple sclerosis
M. Braitch et al.
ACTA NEUROLOGICA SCANDINAVICA (2009)
Expression of TLR9 within human glioblastoma
Yuxia Meng et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Incidence of symptomatic hemorrhage after stereotactic electrode placement
Charles A. Sansur et al.
JOURNAL OF NEUROSURGERY (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors
Abdeljabar El Andaloussi et al.
GLIA (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
TLR signaling tailors innate immune responses in human microglia and astrocytes
CS Jack et al.
JOURNAL OF IMMUNOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Surgical and hardware complications of subthalamic stimulation - A series of 160 procedures
KE Lyons et al.
NEUROLOGY (2004)
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
AM Krieg et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors
JH Sampson et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
CpG-oligonucleotides for cancer immunotherapy: Review of the literature and potential applications in malignant glioma
AF Carpentier et al.
FRONTIERS IN BIOSCIENCE (2003)
Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells
F Takeshita et al.
JOURNAL OF IMMUNOLOGY (2001)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
